UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC
Financial Performance:
- As a pre-revenue clinical-stage company, Cardiff Oncology reported no revenue or earnings; financial metrics focus on liquidity.
- Cash balance stands at approximately $34 million (as of end of Q3), with runway extending through Q3 2027.
- No specific debt, deferred revenue, or cash flow generation data provided as the company is in development stages.
Guidance and Future Outlook:
- Targeting the start of the Phase 3 registration trial for Onvancitib in first-line metastatic RAS-mutated colorectal cancer (mCRC) in Q1 2027, utilizing a staged initiation approach.
- Regulatory pathway includes potential for accelerated approval based on Overall Response Rate (ORR) and full approval based on Progression-Free Survival (PFS).
- Awaiting final feedback from European regulators regarding the Phase 3 design and endpoints.
- Long-term goal is to establish a new treatment paradigm for the ~50% of mCRC patients with RAS mutations, a population with no approved targeted therapies in 20 years.
Business Segments and Product Lines:
- Lead Asset (Onvancitib): A selective PLK1 inhibitor receiving Fast-Track designation (announced Friday prior to call) and Orphan Drug designation for Chronic Myelomonocytic Leukemia (CMML) and Small Cell Lung Cancer (SCLC).
- Primary Indication: Phase 2 trial (CARD004) results support Phase 3 enrollment of Onvancitib (30mg) + FOLFIRI + Bevacizumab for first-line mCRC with pan-RAS mutations.
- Secondary Indications: Promising monotherapy signals observed in relapsed/refractory CMML (40% response rate) and SCLC; data to be updated at the upcoming American Society of Hematology (ASH) meeting.
- Strategic Shift: Focus on first-line setting for RAS-mutated mCRC, distinguishing from competitors targeting Microsatellite Stable (MSS) or G12C-specific populations.
Market and Competitive Landscape:
- Market Opportunity: Addresses ~50% of mCRC patients harboring RAS mutations (NRAS, KRAS), a high-unmet-need segment with historically poor overall survival.
- Competitive Differentiation: Unlike competitors pursuing immunotherapy (PD-1/PD-L1 + VEGF) or KRAS G12C inhibitors (limited to a fraction of RAS mutants), Cardiff targets the entire RAS-mutated population.
- Market Gap: No novel targeted therapies approved for this indication in the last two decades; standard of care remains chemotherapy and Bevacizumab (now generic).
- Mechanism of Action: Onvancitib demonstrates synergy with Irinotecan by inhibiting HIF-1-alpha (anti-angiogenesis) and blocking PLK1-mediated DNA damage repair, creating a "two-punch" effect.
Risks and Challenges:
- Trial Execution: Phase 3 study relies on pending funding; initiation is contingent on securing sufficient capital before Q1 2027.
- Regulatory Uncertainty: Final approval depends on the maturation of PFS data in the Phase 3 trial; accelerated approval is contingent on compelling ORR and durability data.
- Clinical Risk: The Phase 2 study was not powered for PFS, requiring the larger Phase 3 trial to confirm statistical significance and long-term benefit.
- Competitive Landscape: Risk that other companies targeting MSS populations or specific G12C mutations may capture market share before Onvancitib achieves approval.
Management Commentary and Tone:
- Tone: Highly confident and optimistic, emphasizing "compelling" efficacy data and a clear path to market.
- CEO Commentary: Mani Mohindru highlighted the 70%+ ORR vs. 42% in controls and the ability to enable curative surgery in a subset of patients.
- Regulatory Relationship: Praised FDA collaboration, noting successful End-of-Phase 2 meetings that validated the Phase 3 design, dose (30mg), and chemo backbone (FOLFIRI/Bev).
- Operational Readiness: Management expressed confidence in CRO selection and readiness to commence trials pending funding.
Analyst Questions and Answers:
- Note: Specific analyst Q&A details were not included in the provided transcript text; the section reflects the management presentation's summary of interactions.
- Regulatory Feedback: Confirmed FDA agreement on using ORR for accelerated approval and PFS for full approval within a single study.
- Chemo Selection: Management explained the selection of FOLFIRI over FOLFOX due to the mechanistic synergy between Irinotecan and Onvancitib (HIF-1-alpha inhibition and DNA repair blockade), whereas FOLFOX (Oxaliplatin) lacks this synergy.
Other Key Points:
- Durability: Patients on the 30mg Onvancitib + FOLFIRI arm have remained on treatment for >21 months; median PFS has not been reached in the treatment arm compared to 11 months in the control arm.
- Surgery Potential: A notable number of patients in the treatment arm achieved tumor shrinkage sufficient to undergo curative-intent surgery, a rare outcome in first-line mCRC.
- Broad Enrollment: Phase 2 included high-risk patients with liver metastases and multi-organ involvement, demonstrating efficacy across the board regardless of baseline characteristics.
- Mechanism Validation: Preclinical data confirmed that RAS-mutated cancers rely heavily on PLK1, validating the synthetic lethality approach.
- Company
- CARDIFF ONCOLOGY INC
- Keywords
- CARDIFF ONCOLOGY INC